Lymphoma Trial, Recruiting NCT06832228 Sponsor: Zhejiang Cancer Hospital Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT06832228
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part voluntarily, have signed a consent form, and are expected to follow the study requirements
  • People aged 18 to 80 years old at the time of signing the consent form, with a general health and activity level rated 0–2 on a standard oncology scale (meaning able to carry out at least some daily activities) (confirm with trial site)
  • People who have been diagnosed with diffuse large B-cell lymphoma (a type of blood cancer) confirmed by a tissue sample, who have measurable signs of disease, and whose cancer did not go into full remission or came back after at least two previous treatments
  • Women of childbearing age who agree to use contraception (such as an IUD, birth control pills, or condoms) throughout the study and for six months after it ends, have had a negative pregnancy blood test within 7 days before joining, and are not breastfeeding; male participants who agree to use contraception during the study and for six months after it ends

Who may not be able to join:

  • People whose lymphoma is specifically located in the brain or spinal cord (primary central nervous system DLBCL), or whose lymphoma is of a type that starts in the chest area called primary mediastinal large B-cell lymphoma
  • People with serious or poorly controlled health conditions, including heart failure with symptoms, uncontrolled high blood pressure, unstable chest pain (angina), active stomach ulcers, or serious bleeding disorders such as haemophilia A, haemophilia B, von Willebrand disease, or a history of spontaneous bleeding that needed a transfusion or other medical treatment
  • People with a history of an active immune or autoimmune disease, or who have previously received a donated organ transplant or donated stem cell transplant
  • People who have had an active infection requiring antibiotics, antifungals, or antiviral medicines within the 14 days before starting the study treatment
  • People who are currently taking part in another clinical trial, or who finished a previous clinical trial's treatment less than 4 weeks ago
  • People who, in the treating doctor's judgment, have other health conditions that could put them at serious risk or interfere with completing the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Haiyan Yang, PhD, Zhejiang Cancer Hospital

Phone: 15157155533

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Zhejiang Cancer Hospital
Registry
ClinicalTrials.gov
Start date
1 September 2024
Est. completion
1 September 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov